Long-term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets in the CLARITY and CLARITY Extension Studies

被引：0

作者：

Giovannoni, G. ^{[1
]}

Comi, G. ^{[2
,3
]}

Rammohan, K. ^{[4
]}

Rieckmann, P. ^{[5
,6
]}

Vermersch, P. ^{[7
]}

Dangond, F. ^{[8
]}

Keller, B. ^{[9
]}

Jack, D. ^{[9
]}

机构：

[1] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England

[2] Univ Vita Salute San Raffaele, Dept Neurol, Osped San Raffaele, Milan, Italy

[3] Univ Vita Salute San Raffaele, Inst Expt Neurol, Osped San Raffaele, Milan, Italy

[4] Univ Miami, Sch Med, MS Res Ctr, Miami, FL USA

[5] Med Pk Loipl, Ctr Clin Neuroplast, Erlangen, Germany

[6] Univ Erlangen Nurnberg, Erlangen, Germany

[7] Univ Lille, INSERM, CHU Lille, FHU Imminent,U1172, Lille, France

[8] EMD Serono Res & Dev Inst Inc, Billerica, MA USA

[9] Merck KGaA, Darmstadt, Germany

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2020年 / 27卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EPR3084

引用

页码：468 / 468

页数：1

共 50 条

[21] Innate immune cell counts in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY extension
Soelberg-Sorensen, P.
Dangond, F.
Hicking, C.
Giovannoni, G.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 598 - 599
[22] Absolute lymphocyte count recovery in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY Extension
Soelberg-Sorensen, Per
Dangond, Fernando
Hicking, Christine
Giovannoni, Gavin
NEUROLOGY, 2017, 88
[23] Absolute lymphocyte count recovery in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY Extension
Soelberg-Sorensen, Per
Dangond, Fernando
Hicking, Christine
Giovannoni, Gavin
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (13) : NP12 - NP12
[24] Innate immune cell counts in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) treated with cladribine tablets 3.5mg/kg in CLARITY and CLARITY extension
Soelberg-Sorensen, P.
Dangond, F.
Hicking, C.
Giovannoni, G.
EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 528 - 528
[25] Year-by-year lymphopenia rates in patients with relapsing multiple sclerosis (RMS) treated with cladribine tablets 3.5mg/kg in CLARITY and re-treated in CLARITY Extension
Cook, Stuart
Comi, Giancarlo
Giovannoni, Gavin
Rieckmann, Peter
Soelberg-Sorensen, Per
Vermersch, Patrick
Dangond, Fernando
Hicking, Christine
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (13) : NP11 - NP11
[26] Year-by-year lymphopenia rates in patients with relapsing multiple sclerosis (RMS) treated with cladribine tablets 3.5mg/kg in CLARITY and re-treated in CLARITY Extension
Cook, S.
Comi, G.
Giovannoni, G.
Rieckmann, P.
Soelberg-Sorensen, P.
Vermersch, P.
Dangond, F.
Hicking, C.
EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 195 - 196
[27] Long-term lymphocyte counts in patients with RRMS treated with cladribine tablets
Soelberg-Sorensen, Per
Dangond, Fernando
Hicking, Christine
Giovannoni, Gavin
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP4 - NP4
[28] Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study
Giovannoni, Gavin
Singer, Barry A.
Issard, Delphine
Jack, Dominic
Vermersch, Patrick
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (08) : 1219 - 1228
[29] Long-Term Lymphocyte Counts in Patients with RRMS Treated with Cladribine Tablets (CT)
Soelberg-Sorensen, P.
Dangond, F.
Hicking, C.
Giovannoni, G.
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (03) : 397 - 397
[30] Disability improvement in relapsing-remitting multiple sclerosis patients receiving cladribine tablets, evaluated by expanded disability status scale
Sormani, M. P.
Giovannoni, G.
Signori, A.
Alexandri, N.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 215 - 215

← 1 2 3 4 5 →